Ask what kind of evidence is being offered
When someone says a treatment is backed by research, ask which claim the research supports. Is it about a chemical, an approved product or the exact preparation being proposed? Ask whether the work involved people and whether its aim matches the reason you are considering care.
A study asks a research question. A product approval answers a different question about a particular medicine. An enforcement policy says when the government plans to pursue possible drug-law violations; it does not grant FDA approval. Keeping those apart makes a headline much easier to assess.
At the November 3, 2026 check, compounded drugs still receive no advance check for quality, effectiveness or safety by the Food and Drug Administration (FDA).
Source: FDA, Compounding and the FDA: Questions and Answers
What the recent HHS draft actually says
A draft policy announced October 30, 2026 concerns some peptide ingredients used in compounding. The agency behind it is the Department of Health and Human Services, known as HHS.
Section 503A covers drugs made for a named patient’s prescription. This part of federal law applies to state-licensed pharmacies and licensed physicians.
The draft is nonbinding. The draft’s stated HHS intent is to withhold enforcement action when those pharmacies and physicians meet its conditions.
The draft names semax, epitalon, TB-500, KPV, BPC-157 and MOTS-c. It sets conditions, including limits on the exact ingredient and the way it enters the body.
The draft covers single ingredients. It leaves out blends, meaning mixtures of ingredients, and facilities registered under section 503B.
The larger registered makers under section 503B are called outsourcing facilities. They often prepare sterile medicines in batches for hospitals or clinics; sterile means free of living germs.
As checked November 3, 2026, the draft grants no FDA approval. None of those peptides is on the official 503A bulks list, which names extra permitted raw ingredients.
Source: HHS, the draft policy and its appendices
Source: Federal Register, notice announcing the draft policy
This is about how HHS plans to enforce the rules. It grants no right to compound and leaves the law as it stands. It does not turn a treatment offer into an approved drug.
A committee account is different from a changed rule
The official account
The committee was considering which ingredients to recommend for the 503A compounding list.
HHS reports a favorable vote at the July 2026 meeting for six of the seven peptides considered: TB-500, epitalon, KPV, semax, BPC-157 and MOTS-c.
That is an official HHS account. FDA’s meeting page had no transcript, roll-call record or minutes of the discussion as of November 3, 2026. The HHS account still tells you what the committee advised.
For your proposed medicine, ask about the current rule and product status even when a favorable vote is reported.
The rule itself
The committee advises FDA; its vote does not change the bulk-ingredient regulation.
FDA uses a formal public rulemaking process to change that list.
If an offer describes a vote as approval, ask which approval record or enacted rule it means. Ask the clinician to connect that record to the exact ingredient and form being proposed.
Source: FDA, July committee meeting materials
Source: FDA, bulk substances used under the pharmacy compounding provisions
Read the scope before the conclusion
Does a claim concern all preparations, a particular route or a particular need? A route means how a substance enters the body. Ask for the scope in the same conversation as the conclusion; otherwise a narrow statement can sound much broader than it is.
FDA identifies April 22, 2026 as the date its page was current. The groups that asked FDA to add ingredients to the pharmacy compounding list later took back those requests. FDA still lists potential significant safety concerns beside the withdrawn ingredients. The page gives no individual withdrawal dates, so it does not tell you when the request for a particular ingredient was taken back.
Taking back a request neither gives legal permission to compound nor means FDA has cleared the ingredient’s safety. Withdrawal does not move an ingredient into FDA’s separate Category 1 group.
Category 1 is FDA’s group for certain raw drug ingredients still being reviewed for its list. For this group, FDA states an intent to hold back enforcement if compounding meets the guidance’s conditions. That describes planned enforcement; it does not make the drug lawful.
Source: FDA, bulk substances with potential significant safety risks
You can ask someone to show the source and point to the passage that supports the offer. If the answer is still unclear, keep that question open for the clinician rather than trying to turn a headline into a personal treatment decision.